Slide 1: Harnessing B-Cells for Cancer Immunotherapy: A Paradigm Shift in Play
ASX:IMU For personal use only HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY: A Paradigm Shift in Play N ic h o la s E d e , P h D C h ie f Te c h n o lo g y O f fic e r B io s h a re s B io te c h S u m m it Ju ly 27 / 2 01 8
Slide 2: Notice: Forward Looking Statements
NOTICE: FORWARD LOOKING STATEMENTS Any forward looking statements in this presentation have been prepared on For personal use only Im u g e n e L im ite d (A S X :IM U ) the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about f
Slide 3: Imugene develops vaccines to direct the immune system against cancer
For personal use only Imugene develops vaccines to boost and direct the body’s immune system to specifically target and attack cancer cells. 3
Slide 4: A Better Way to Make Antibodies to Treat Cancer?
A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? For personal use only In a facility: Using B-cells in your body VS B-cells are cells in the human body that naturally produce millions of antibodies For example, Merck’s PD-1 inhibitor Keytruda Teaching B-cells to make antibodies using peptide antigen
Slide 5: Monitoring the Competition: Differentiation in a Crowded Market
MONITORING THE COMPETITION: DIFFERENTIATION IN A CROWDED MARKET For personal use only Constant monitoring Constant monitoring of of competitive Imugene position – landscape SWOT analysis Turn threats into Synergistic technology opportunities / acquisition from Ohio weaknesses into State University a
Slide 6: Strategic Acquisition
STRATEGIC ACQUISITION Ohio State University and Mayo Clinic B-cell peptide vaccine portfolio For personal use only ➤ Opportunity to create the pre-eminent, dominant position globally in B-cell peptide vaccines and therapeutics. A catalyst for value creation. ➤ Professor Kaumaya’s work in the area of
Slide 7: OSU Worldwide, Exclusive License
OSU WORLDWIDE, EXCLUSIVE For personal use only LICENSE Ongoing Her- Six additional Three year Six patent IND ready PD- 2 clinical clinical candidates R&D contract families, 1 clinical trial trial Her-1, Her-2, Her- with access to 3, VEGF, IGF-1R Ohio 22 patents (Phase 1) (Phase 2) CD28 translational
Slide 8: Why Select and Target PD-1 for B-Cell Vaccination?
WHY SELECT AND TARGET PD-1 FOR B-CELL VACCINATION? For personal use only Monoclonal antibody immunotherapies Whilst acknowledging the rapid rise in Keytruda® (Merck) and clinical trials involving PD-1 and their Opdivo® (BMS) targeting PD-1 sold combination with other treatments*, a PD-1 USD$3.8B and
Slide 9: PD-1/HER-2 Vaccine Combination Active in Model of Colorectal Cancer
PD-1/HER-2 VACCINE COMBINATION ACTIVE IN MODEL OF COLORECTAL CANCER WITH NO SIGNS OF TOXICITY For personal use only ➤ All mice vaccinated over a period of 9 weeks % Cancer growth inhibition in Colorectal cancer model showed no signs of scruffiness, lesions, and lethargy P D-1 va c ci n e p l u s He
Slide 10: PD-1 Key-Vaxx Vaccine Phase Development Path 2018-2019
PD-1 “KEY-VAXX” VACCINE PHASE 1 DEVELOPMENT PATH 2018-2019 For personal use only Finalise PD-1 Formal regulatory IND 2019: CMC Commence candidate vaccine manufacturing pre-clinical submissions Phase 1 Identified May, 2018 Proposed Adaptive Phase 1/2 Expansions Assumption PD-1 Vaccine Design Cohort 3
Slide 11: Immuno-Oncology Combinations Driving Value
IMMUNO-ONCOLOGY COMBINATIONS DRIVING VALUE For personal use only ➤ Combining drugs for better I/O outcomes is driving value creation presently ➤ Big Pharma are looking for novel combinations or “elusive blends” that: • Combine without increasing toxicity • Combine with minimal cost increase • Combin
Slide 12: Combination Example
COMBINATION EXAMPLE For personal use only July 2018, FDA approves Opdivo plus Yervoy The FDA approval of combination for a combination Opdivo certain subset of and Yervoy provides Unfortunately, more patients with a novel therapeutic significant toxicity is metastatic option with a higher noted with
Slide 13: Professor Pravin Kaumaya & Dr. Tanios Bekaii Saab Editorial
PROFESSOR PRAVIN KAUMAYA & DR. TANIOS BEKAII SAAB For personal use only For reprint orders, please contact: reprints@futuremedicine.com Could precision-engineered Editorial Future Oncology peptide epitopes/vaccines be the key to a cancer cure? “Combination cancer vaccines with peptide mimics have th
Slide 14: A Team with Track Record in Drug Development
A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT Leslie Chong (Sydney, Australia) Dr Nick Ede (Melbourne, Australia) For personal use only Managing Director & Chief Executive Officer Chief Technology Officer • Over 20 years of oncology experience in Phase I – III of • Over 25 years peptide vaccine and d
Slide 15: Imugene Scientific Advisory Board
IMUGENE SCIENTIFIC ADVISORY BOARD For personal use only Professor Peter Schmid (Barts Cancer Inst., Prof Ursula Wiedermann (Vienna, Austria) London) Chief Scientific Officer Chair of Cancer Medicine, Queen Mary Hospital London • Co-inventor of HER-Vaxx • Expertise in breast and lung cancer, cancer i
Slide 16: Executive Summary
EXECUTIVE SUMMARY For personal use only Imugene B-cell Vaccine Pipeline Synergistic Technology Broadened and Acquisition from strengthened clinical Experienced Ohio State University programs globally, brings Management & the Imugene platform and and The Mayo Clinic technology into US Board Full spec